The incidence rate of ICI-related pancreatitis ranges from 2-8% (2% with CTLA-4 inhibitor, 4% with PD-1/PD-L1 inhibitor, and 8% with combination therapy) [53]. Here, CTLA4 is linked to pancreatitis.